Please login to the form below

Not currently logged in
Email:
Password:

Merck collaborate over betrixaban

Merck and Portola Pharmaceuticals have signed an exclusive global collaboration and license agreement for betrixaban

Global research-driven pharmaceutical company, Merck & Co, and Portola Pharmaceuticals have signed an exclusive global collaboration and license agreement for the development and commercialisation of betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in phase II clinical development for the prevention of stroke in patients with atrial fibrillation (SPAF).

In return for an exclusive worldwide license to betrixaban, Merck will pay Portola an initial fee of $50m. Portola is also eligible to receive additional cash payments amounting to $420m on achievement of certain development, regulatory and commercialisation milestones, as well as double-digit royalties on worldwide sales of betrixaban, if approved. Merck will assume all development and commercialisation costs, including the costs of phase III clinical trials, however, Portola has retained an option to co-fund phase III clinical trials in return for additional royalties and to co-promote betrixaban with Merck in the US.

According to Dr Luciano Rossetti, senior vice president and franchise head, atherosclerosis and cardiovascular at Merck Research Laboratories: "This agreement reinforces Merck's focus on developing an innovative portfolio of products for the treatment and management of multiple aspects of cardiovascular disease."

13th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics